On September 2, 2026, Eisai China announced that the lecanemab (brand name: Leqembi) autoinjector pen has received approval from the National Medical Products Administration (NMPA) for the initial treatment of early Alzheimer’s disease (AD). This follows the US Food and Drug Administration (FDA) approval of the same device in July 2026, making China the second country globally and the first in Asia to approve the autoinjector. Anti-amyloid monoclonal antibody therapies, represented by lecanemab, have ended a more than thirty-year drought of breakthrough progress in Alzheimer’s treatment and brought a critical inflection point for early patients to slow disease progression. Approval of this new autoinjector marks China’s entry into a new stage of at-home management for Alzheimer’s disease.
From Hospital to Living Room: Returning Time to Life
The lecanemab subcutaneous autoinjector pen moves treatment from hospital-based intravenous infusion into the home, and was recognized on TIME magazine’s “2025 Best Inventions” list in the Medical & Health category. The dosing regimen is 500 mg weekly, given as two 250 mg subcutaneous injections, fully automated and precisely delivered, with clinical efficacy comparable to the intravenous formulation. The pen can be operated at a single button press with ultra-fine needles and a transparent window, producing minimal pain. At-home injection also eliminates direct costs such as infusion fees and travel, and avoids the agitation and discomfort associated with prolonged stays in infusion rooms; treatment time is reduced by 99%, delivering an experience that combines multiple efficacy outcomes with fully automated injection, time savings, and peace of mind. This innovation in route of administration is tailored to the needs of AD patients — shifting not only the treatment setting but the feasibility of sustained therapy, making it easier for early patients to seize the golden window (mild cognitive impairment [MCI] due to AD and mild AD dementia) and initiate and continue treatment in time, returning the time previously spent traveling to hospitals to family togetherness and free living.
Prof. Jia Jianping, Director of the Neurology Disease High-Creation Center at Xuanwu Hospital, Capital Medical University, stated: “Alzheimer’s disease is a major public health threat to the health of older adults in China. The launch of the lecanemab subcutaneous autoinjector pen represents not only an innovation in route of administration in the history of AD treatment, but also a substantive step in the ‘precision’ direction of China’s elderly health services. The autoinjector pen efficiently clears Aβ protein through multiple targets at the source; while ensuring potent pathological intervention, it further reduces systemic injection-related reactions, providing a comprehensive upgrade in convenience and offering a sustainable path for long-term standardized management. It truly makes ‘early treatment''sustainable over the long term, which is more conducive to slowing disease progression. This is also aligned with the national strategy of actively responding to population aging and helps support dignified aging.”
Treat Early Now: Seize the AD Golden Window and Protect Life and Dignity
China currently has nearly 17 million patients with Alzheimer’s disease and related dementias [1], and the mortality rate continues to rise, making AD the sixth leading cause of death in the Chinese population [2]. More notably, only 28.6% of Chinese patients with early Alzheimer’s disease receive a diagnosis [3], and most patients are already in the moderate-to-severe stage at diagnosis.
In fact, before severe cognitive decline, there is a brief “golden window” in the mild dementia stage, with disease course typically lasting 1 to 3 years (with significant individual variation). At this stage, patients have begun to show subtle abnormalities such as memory decline, slowed speech, and impaired executive function, but daily living is still largely independent and the brain has not yet suffered irreversible severe damage. Timely intervention during this phase can effectively slow disease progression and preserve patients’ functional capacity and dignity. Once the window is missed and the disease progresses to moderate-to-severe stages, the brain suffers irreversible severe functional decline. Therefore, early detection, early diagnosis, and early treatment are decisive for the patient’s future quality of life.
Zhou Yang, President of Eisai China, said: “The approval of the lecanemab subcutaneous autoinjector pen is a milestone in the field of Alzheimer’s disease treatment, bringing home-based treatment truly into millions of households and enabling more early AD patients to receive standardized, continuous treatment in the familiar home environment. In the future, Eisai will continue to deepen its work in AD prevention and treatment, partnering with all sectors of society to build a full-chain prevention-and-treatment ecosystem spanning early screening, early diagnosis, and standardized treatment, so that more patients in China can benefit from early treatment — together protecting the memory and dignity of millions of families.”
References
[1] China Alzheimer’s Disease Report 2025. Released under the lead of the Department of Neurology, Renji Hospital, Shanghai Jiao Tong University School of Medicine. September 2025.
[2] National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University; Chronic Non-Communicable Disease Prevention and Control Center, Chinese Center for Disease Control and Prevention; Capacity Building and Continuing Education Center, National Health Commission; China Population and Development Research Center; China Alzheimer’s Disease Blue Book Project Team. China Alzheimer’s Disease Blue Book (Condensed Edition). Chinese Medical Journal, 2024,104(29):2701-2727. DOI:10.3760/cma.j.cn12137-20240416-00883.
[3] China News Service. March 2025. Experts call for multi-party collaboration to promote early diagnosis and treatment of Alzheimer’s disease. China News Service.